France Frontotemporal Disorders Therapeutics Market Report 2022 to 2030

France Frontotemporal Disorders Therapeutics Market Analysis

$ 3999

France Glioblastoma Multiforme Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Neurons in the frontal and temporal lobes of the brain are damaged in frontotemporal diseases (FTD), also known as frontotemporal dementia. As the patient population for FTD is growing, non-profit organisations, illness advocacy groups, and private organisations are currently concentrating on supporting treatment research. A major driver of the frontotemporal disorders treatment market growth is predicted to be the rising life expectancy rate, which is also expected to contribute to the increasing prevalence of neurological diseases among the older population. Apotex Inc., AstraZeneca plc., Auro Pharma, Johnson & Johnson, Mylan N.V., Pfizer Inc., Sanofi S.A., and Teva Pharmaceuticals USA, Inc. are just a few of the well-known worldwide and local businesses that are examined in the competitive landscape.

ID: IN10FRRD026 CATEGORY: Rare Diseases GEOGRAPHY: France AUTHOR: Nipun Arora

Buy Now

France Frontotemporal Disorders Therapeutics Market Analysis Summary

France Frontotemporal Disorders Therapeutics Market is valued at around $9.5 Mn in 2022 and is projected to reach $13.11 Mn by 2030, exhibiting a CAGR of 4.1% during the forecast period 2023-2030.

The brain's frontal and temporal lobes contain neurons that can get damaged, leading to frontotemporal disease (FTD), also known as frontotemporal dementia. Unusual behaviours, emotional issues, communication difficulties, work difficulties, and walking difficulties are just a few of the many potential signs that could manifest. Unlike other types of dementia, FTD is uncommon and usually manifests earlier in life. 60 per cent of FTD sufferers are between the ages of 45 and 64. FTD can be challenging to identify since it exhibits clinical symptoms that can be confused with those of other dementias or psychiatric conditions. Between the onset of symptoms and a proper diagnosis, it takes, on average, 3.6 years. Imaging and blood or cerebrospinal fluid investigations are currently used in the diagnosis of FTD.

As the patient population for FTD is growing, non-profit organisations, illness advocacy groups, and private organisations are currently concentrating on supporting treatment research. A major driver of the frontotemporal disorders treatment market growth is predicted to be the rising life expectancy rate, which is also expected to contribute to the increasing prevalence of neurological diseases among the older population.

Apotex Inc., AstraZeneca plc., Auro Pharma, Johnson & Johnson, Mylan N.V., Pfizer Inc., Sanofi S.A., and Teva Pharmaceuticals USA, Inc. are just a few of the well-known worldwide and local businesses that are examined in the competitive landscape.

Market Dynamics

Market Drivers

Aiming to Develop More FTD Drugs While Raising More Money As the patient population for FTD is growing, non-profit organisations, illness advocacy groups, and private organisations are currently concentrating on supporting treatment research. Numerous non-profit organisations, including the Association for Frontotemporal Degeneration (AFTD), Bluefield Project Organization, Tau Consortium Organization, Alzheimer Discovery Foundation (ADDF), and CurePSP, Inc., have supported research funding initiatives for drugs to treat frontotemporal disorders. These groups support both preclinical and clinical research exploring potential medicines that are intended to reduce or stop the progression of FTD and other uncommon neurological diseases. This accelerates market expansion.

Growing demand for user-friendly medications: Oral medications are anticipated to drive market expansion. Given that the majority of medications are accessible in capsule and tablet form and that this is a very practical mode of administration, the category is anticipated to accelerate the global market.

Increase in the Senior Population: Due to the high prevalence of neurological diseases among the elderly population, an increase in life expectancy is another major factor anticipated to propel the growth of the frontotemporal disorders treatment market. Neurodegenerative illnesses such as frontotemporal disorder, Alzheimer's, and dementia often affect those 65 and older. As a result, this demographic requires improved treatment alternatives, which opens up new market expansion potential.

Market Development

Alaunos Therapeutics is currently in Phase II of its TCR-T Library clinical trial for glioblastoma multiforme (GBM).

The FDA authorised Auvelity, the first oral medication with quick action for severe depressive illness, in August 2022. (MDD).

In April 2022, the US FDA gave Lupin Ltd permission to put its generic version of the antidepressant medicine Desvenlafaxine extended-release tablets on the market.

Restraints of France Glioblastoma Multiforme Therapeutics Market

Misdiagnosis of Neurological Disorders: A number of frontotemporal disorders are frequently misdiagnosed as psychiatric disorders like depression, Parkinson's, Alzheimer's, or other psychiatric problems, which makes it more difficult to treat neurological disorders.

Failure rates of clinical trials: Although clinical trials have produced many therapies other than pharmaceuticals, the persistently high failure rates of clinical trials are a significant factor impeding the growth prospects of treating neurological diseases. As a result, it prevents the market from expanding.

Key players

Biogen Novartis Roche Sanofi Alnylam Pharmaceuticals Ionis Pharmaceuticals Genzyme Sangamo Therapeutics Magenta Therapeutics Ceregene

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For France Glioblastoma Multiforme Therapeutics Market

By Drug Class

Antidepressants
Selective serotonin reuptake inhibitors
Serotonin and noradrenaline reuptake inhibitors
Antipsychotics
Cognitive Enhancers
RIsperidone
Quetiapine
Others

By Disease Indication

Frontotemporal Dementia
Primary Progressive Aphasia
Movement Disorders

By Treatment

Behavioural Symptoms Management
Psychological Symptoms Management

By Route of Administration

Oral
Parenteral

By End-Users

Hospitals
Homecare
Speciality Centres
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.